Literature DB >> 8915137

Measurement of disease activity and outcome in atopic dermatitis.

A Y Finlay1.   

Abstract

Many different systems have been proposed for the recording and measurement of disease activity in atopic dermatitis (AD). This review describes the techniques that have been used and published in recent years for clinical evaluation and for objective measurement of AD, as well as for recording its effects on quality of life. Recommendations are made concerning which methods should be used.

Entities:  

Mesh：

Year:  1996        PMID： 8915137

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  14 in total

1.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors:  Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

2.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 3.  Treatment of cutaneous lupus.

Authors:  Aileen Y Chang; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

Review 4.  Clinical outcome measures for cutaneous lupus erythematosus.

Authors:  J Albrecht; V P Werth
Journal:  Lupus       Date:  2010-08       Impact factor: 2.911

5.  Effects of allergic dermatosis on health-related quality of life.

Authors:  R T Anderson; R Rajagopalan
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

6.  Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Kathryn S Torok; Thomas A Medsger
Journal:  Rheumatology (Oxford)       Date:  2009-12-14       Impact factor: 7.580

7.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

8.  Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method.

Authors:  Marjolein G Willemsen; Rosalinda W C van Valburg; Pauline C Dirven-Meijer; Arnold P Oranje; Johannes C van der Wouden; Heleen Moed
Journal:  Dermatol Res Pract       Date:  2009-11-18

9.  Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.

Authors:  Misha Rosenbach; Howa Yeung; Emily Y Chu; Ellen J Kim; Aimee S Payne; Junko Takeshita; Carmela C Vittorio; Karolyn A Wanat; Victoria P Werth; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

Review 10.  Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids.

Authors:  Roman Schiffner; Julia Schiffner-Rohe; Michael Landthaler; Wilhelm Stolz
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.